Facebook
Twitter
LinkedIn
Forward2023 SNO/ASCO CNS Cancer Conference
The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Click Register/Take Course to Claim Credit
Please log in using the SNO account created during Registration.
The Access Code can be found in the Post Conference Email.
For technical assistance with claiming CME credit, please email academy@soc-neuro-onc.org .
2023 SNO/ASCO CNS Cancer Conference
August 10-12, 2023
Hyatt Regency Embarcadero - San Francisco, California
Overview
The 2023 SNO/ASCO CNS Cancer Conference — Accelerating therapeutic discovery and advancing care of patients with primary and metastatic CNS malignancies — will be held August 10-12, 2023, in San Francisco, California. The goal of this annual conference is to provide a deeper dive into the basic science of brain metastases and neuro-oncology clinical trials. Together, we will make significant improvements in survival and quality of life of patients with primary and metastatic cancers of the central nervous system.
This collaborative conference will:
stimulate basic, translational, and clinical research in CNS metastases;
engage clinical researchers in innovative trial designs for primary and secondary CNS malignancies;
address the needs of patients with intracranial tumors.
These areas of great unmet need will be addressed in a dynamic and interactive framework. The structure brings together various disciplines to emphasize basic and translational research on brain metastases as well as clinical trial design and outcomes in primary and metastatic intracranial tumors. Research highlighting novel approaches, innovative ideas, and recent advances in neuro-oncology clinical trials will be presented and discussed. There will be a unique opportunity for collaboration and exchange of ideas between those dedicated to the science and care of patients with primary and secondary malignancies of the CNS.
Target Audience
Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care Professionals, Industry Professionals, Regulatory and Government Officials, Patient Advocates and Nursing Professionals.
Learning Objectives
- Explain new CNS-penetrant systemic agents in the context of multidisciplinary care for the treatment of CNS metastases.
- Discuss new developments in local therapeutic approaches and diagnostics in the treatment of CNS metastases.
- Explain the role of the tumor microenvironment in CNS metastases.
- Compare clinical trials designs incorporating recent advances such as liquid biopsy, novel prognostic biomarkers, and advanced neuroimaging for the treatment of CNS malignancies.
- Outline challenges for the development and approval of novel therapies for CNS cancers.
Horizontal Tabs
Planning Committee Leadership
Co-Chairs
Adrienne Boire, Memorial Sloan Kettering Cancer Center
Sarah Goldberg, Yale School of Medicine
Co-Chairs Elect
Priya Kumthekar, Northwestern Medicine
Hussein Tawbi, University of Texas MD Anderson Cancer Center
Immediate Past Co-Chairs
Priscilla Brastianos, Massachusetts General Hospital, Harvard Medical School
Mustafa Khasraw, Duke University
Planning Committee
Stephen Bagley, University of Pennsylvania
Evanthia Galanis, Mayo Clinic Rochester
Vinai Gondi, Northwestern Medicine Cancer Center Warrenville and Proton Center
Jona Hattangadi-Gluth, University of California, San Diego
Sara Hurvitz, University of California, Los Angeles
Emilie Le Rhun, University Hospital Zurich, Switzerland
Nancy Lin, Dana Farber Cancer Institute
Minesh Mehta, Miami Cancer Institute
Josh Neman, University of Southern California, Los Angeles
Michael Platten, University Medical Center Mannheim
Solmaz Sahebjam, National Cancer Institute, National Institutes of Health
Debra Nana Yeboa, University of Texas MD Anderson Cancer Center
The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 11.25 AMA PRA Category 1 Credit™This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Society for Neuro-Oncology. The Society for Neuro-Oncology is accredited by the ACCME to provide continuing medical education for physicians.
- 11.25 Attendance
Price
Instructions to Receive Credit
Click Register/Take Course on the top menu bar to continue to claim credit.
Log in using the email address and password used during the registration process.
Click Register, then Enter the Access Code.
Click Unlock.
*The access code can be found in the post conference email.
Click Take Course to begin the credit claiming process.
Follow the course instructions to claim credit and receive certificates.